Related by context. All words. (Click for frequent words.) 74 target vessel revascularization 72 repeat revascularization 72 binary restenosis 71 reintervention 71 MACCE 70 ischemia driven 69 TAXUS Express Stent 69 Target Lesion Revascularization TLR 68 Taxus Stent 68 events MACE 68 sirolimus eluting stent 68 reinfarction 67 XIENCE V PROMUS Stent 67 TAXUS p value 66 Events MACE 66 ID TLR 66 TAXUS Stent 66 stent thromboses 66 revascularization 66 nonfatal myocardial infarction 65 XIENCE V demonstrated 65 TAXUS stent 65 CYPHER ® Stent 65 diameter stenosis 65 paclitaxel eluting stents 65 reoperation 64 TAXUS 64 revascularisation 64 definite stent thrombosis 64 mm Stent 64 ipsilateral stroke 64 XIENCE V vs. 64 resuscitated cardiac arrest 63 Major Adverse Cardiac 63 primary patency 63 coronary revascularization 63 revascularizations 63 Operative mortality 63 restenosis 63 percutaneous intervention 62 myocardial infarction MI 62 stenting 62 angiographic restenosis 62 periprocedural 62 sirolimus stent 62 paclitaxel eluting stent 61 composite endpoint 61 nondiabetic patients 61 CYPHER R Stent 61 coronary interventions 61 CYPHER Stent 61 stent implantation 61 systemic embolism 61 refractory ischemia 61 LVEF 61 acute myocardial infarction AMI 60 TAXUS Liberte Stent 60 ischemic complications 60 cardiovascular hospitalizations 60 failure TVF 60 revascularization procedure 60 revascularization procedures 60 nonfatal MI 60 thromboembolic events 60 XIENCE V stent 60 TAXUS Express 60 biochemical recurrence 60 recurrent ischemia 60 unstable angina pectoris 60 sirolimus eluting stents 60 neointimal hyperplasia 60 Free Survival PFS 59 stented 59 transfemoral 59 pCR 59 TAXUS Liberte Long 59 myocardial infarction stroke 59 tirofiban 59 perioperative mortality 59 stent restenosis 59 TAXUS Element Stent 59 Cypher Stent 59 stent thrombosis 59 Stent thrombosis 59 everolimus eluting stents 59 annualized relapse 59 binary restenosis rate 59 recanalization 59 rebleeding 59 FFR guided 58 undergoing coronary artery 58 plus dexamethasone 58 angiographic outcomes 58 myocardial infarction 58 arterial thromboembolic events 58 fraction LVEF 58 OPCAB 58 uncoated stent 58 postoperative mortality 58 deep venous thromboses 58 bivalirudin 58 segment binary restenosis 58 STEMI patients 58 thromboembolism 58 HF hospitalization 58 ischemic cardiomyopathy 58 perioperative complications 58 thrombotic events 58 endarterectomy 58 primary percutaneous coronary 58 stent BMS 58 fatal myocardial infarction 58 placebo dexamethasone 58 plus gemcitabine 58 TEAEs 58 locoregional disease 58 HBeAg seroconversion 58 discontinuations due 58 ST elevation myocardial 58 everolimus eluting stent 58 angioplasty stenting 58 target lesion revascularizations 58 stent binary restenosis 58 locoregional recurrence 57 fibrinolysis 57 TAXUS Express Atom Stent 57 peri procedural 57 sirolimus eluting 57 multivessel disease 57 infarct size 57 myocardial infarctions 57 postintervention 57 distant metastasis 57 TAXUS Liberté stent 57 KRAS wild 57 saphenous vein grafts 57 oral allopurinol 57 sustained virological response 57 CR nPR 57 patients undergoing CABG 57 lopinavir r arm 57 Kaplan Meier analysis 57 hepatic resection 57 cytogenetic response 57 cerebrovascular events 57 CABG 57 cardiovascular hospitalization 57 IIIa inhibitor 57 luminal diameter 57 carotid artery stenting CAS 57 Target Vessel Revascularization 57 patency 57 Erythropoietic therapies may 57 NEVO ™ 57 radical nephrectomy 57 coronary artery bypass grafts 57 reoperations 57 Flu Cy 57 receiving prophylactic anticoagulation 57 nonfatal stroke 57 CABG surgery 56 bypass graft CABG surgery 56 stented artery 56 arterial revascularization 56 Kaplan Meier estimates 56 abciximab 56 recurrent VTE 56 coronary stenting 56 PSA nadir 56 stenoses 56 carotid endarterectomy 56 recurrent myocardial infarction 56 non valvular atrial 56 TAVR 56 Complication rates 56 chlorambucil 56 nadolol 56 vertebral fracture 56 p = #.# [004] 56 atheroma volume 56 hip BMD 56 achieved ACR# 56 ejection fractions 56 rosuvastatin #mg 56 lymphadenectomy 56 Myocardial Infarction Study 56 prospectively stratified 56 Median progression 56 FOLFOX4 56 inhospital 56 infarction STEMI 56 glycated hemoglobin levels 56 PASI scores 56 Scale EDSS 56 bypass grafting 56 stage IIIb IV 56 endoleaks 56 eptifibatide 56 silent ischemia 56 carotid artery blockage 56 TAXUS Express2 56 LV dysfunction 56 preintervention 56 de novo lesions 56 morphometric vertebral fractures 56 transurethral resection 56 CYPHER R Sirolimus eluting 56 renarrowing 56 plus GP IIb 56 myocardial reperfusion 56 endoscopic remission 55 nonfatal myocardial infarction MI 55 stent DES 55 aplastic anemia AA 55 left ventricular dysfunction 55 SYNTAX trial 55 Drug eluting stent 55 defibrillator CRT D 55 neointimal 55 workhorse lesions 55 carotid revascularization 55 estimated glomerular filtration 55 p = NS 55 discontinuations 55 severe neutropenia 55 systolic dysfunction 55 secondary efficacy endpoint 55 zotarolimus eluting stent 55 Index CDAI score 55 graft patency 55 ventricular dysfunction 55 Percutaneous Coronary Intervention 55 P = .# 55 percutaneous transluminal coronary angioplasty 55 CCyR 55 reblockage 55 carotid stenosis 55 patients undergoing percutaneous 55 baseline HbA1c 55 percutaneous coronary intervention 55 HbA 1c levels 55 nonobstructive CAD 55 mg kg dose 55 TACE 55 tenecteplase 55 left ventricular systolic 55 TAXUS Liberte stent 55 hemoglobin A1c levels 55 PSADT 55 Median survival 55 virologic failure 55 TAVI 55 VAD implantation 55 baseline A1C 55 DAS# remission 55 Secondary endpoints 55 coronary artery bypass grafting 55 tumor resection 55 oxycodone CR 55 Stent System 55 stents BMS 55 DAPT 55 sustained virologic response 55 postoperative complication 55 troponin T 55 Restenosis 55 mcg albinterferon alfa 2b 55 malperfusion 55 postoperative morbidity 55 biochemical relapse 55 MIs 55 hepatectomy 55 median PFS 55 cytoreductive surgery 55 reinterventions 55 placebo p = 55 coronary intervention 55 thoracoscopic lobectomy 55 VT VF 55 stented vessel 55 prespecified 55 hemorrhagic complications 55 symptomatic VTE 55 stenting procedures 55 PLX STROKE targeting 55 certolizumab 55 VELCADE melphalan 55 angina myocardial infarction 55 unstable angina UA 55 Doxil ® 55 mg QD 54 angiographic 54 prior relapsers 54 paroxysmal AF 54 lumbar spine BMD 54 nonfasting triglyceride levels 54 underwent CABG 54 evaluable 54 HBeAg negative patients 54 NSTE ACS 54 thrombus aspiration 54 complete cytogenetic 54 ACR# responses 54 superficial femoral 54 sternotomy 54 unfractionated heparin UFH 54 Secondary endpoints included 54 Montgomery Asberg Depression 54 intracranial hemorrhage ICH 54 occlusive disease 54 CYPHER ® 54 replacement TAVR 54 preventing restenosis 54 undetectable HBV DNA 54 intracoronary 54 FOLFIRI 54 thromboembolic 54 platelet reactivity 54 NMIBC 54 rFVIIa 54 underwent percutaneous coronary 54 coronary revascularisation 54 Coronary Artery Bypass Graft 54 ACTEMRA TM 54 thrombotic complications 54 CABG surgeries 54 wedge resection 54 oncologic outcomes 54 colectomy 54 transarterial 54 CIMZIA ™ 54 Coronary Stent 54 dose atorvastatin 54 microvascular complications 54 death reinfarction 54 Thrombolysis 54 Secondary endpoints include 54 stable angina 54 infliximab monotherapy 54 pulmonary capillary wedge 54 CHD CVD 54 placebo p 54 lamivudine monotherapy 54 thromboembolic complications 54 MACE 54 plus prednisone 54 Index CDAI 54 bifurcated lesions 54 R0 resection 54 neoadjuvant therapy 54 tapentadol ER 54 carotid stenting 54 advanced adenomas 54 restenotic lesions 54 ICD implantation 54 atrioventricular valve 54 ICD implants 54 revascularized 54 ARCOXIA 54 NIHSS 54 severe exacerbations 54 tumor recurrence 54 adjunctive placebo 54 underwent resection 54 Crohn Disease Activity 54 neoadjuvant 54 A1c levels 54 secondary endpoint 54 distant metastases 54 infrapopliteal 54 irbesartan 54 overlapping stents 54 onset atrial fibrillation 54 unfractionated heparin 54 BMS p = 54 QRS duration 54 #mmHg [001] 54 octreotide LAR 54 percutaneous coronary interventions 54 variceal bleeding 54 Sirolimus eluting Coronary Stent 54 Hb A1C 54 zotarolimus 54 MADRS score 54 Angiographic 54 stent placement 54 nonrandomized 54 RECIST Response Evaluation Criteria 54 balloon valvuloplasty 54 esophagectomy 54 undergoing CABG 54 ALND 53 vessel renarrowing 53 nonoperative 53 asymptomatic carotid stenosis 53 intima media thickness 53 splenectomized patients 53 Abbott bioabsorbable everolimus eluting 53 severe aortic stenosis 53 TAXUS Liberté 53 elective PCI 53 CDAI score 53 resections 53 active comparator 53 urgent coronary revascularization 53 hypoglycemic events 53 lispro 53 underwent surgical resection 53 coronary stenosis 53 cannulation 53 Stenting 53 FluCAM 53 atherothrombotic disease 53 eluting stent 53 Response Evaluation Criteria 53 severe hypoglycemic 53 free survival PFS 53 graft occlusion 53 venous thromboembolic events 53 ventricular tachyarrhythmia 53 TAXUS ® 53 peripheral sensory neuropathy 53 postoperative chemotherapy 53 nicardipine 53 NYHA Class II 53 acute coronary syndromes ACS 53 coronary artery revascularization 53 glycated hemoglobin HbA1c 53 nonvertebral fracture 53 fibrinolytic therapy 53 Primary endpoints 53 dual antiplatelet therapy 53 preoperative chemotherapy 53 CK MB 53 radical prostatectomy RP 53 fondaparinux 53 transapical 53 aortic insufficiency 53 tolvaptan 53 receiving VICTRELIS 53 MitraClip device 53 pulmonary artery banding 53 achieved PASI 53 symptomatic carotid stenosis 53 decitabine 53 prostate TURP 53 IOP lowering 53 NATRECOR R 53 % CI #.#-#.# [003] 53 cardiac dysfunction 53 KRAS mutations occur 53 FOLFOX 53 anthracycline taxane 53 ACR# response 53 plus methotrexate 53 curative resection 53 cisplatin vinorelbine 53 TAXUS TM 53 prespecified secondary 53 rehospitalization 53 progression TTP 53 eplerenone 53 FOLPI 53 #.#/#.# mmHg [001] 53 infarction NSTEMI 53 thrombectomy 53 remission CR 53 circulating EPCs 53 CI #.#-#.# [001] 53 ruptured aneurysms 53 hemodynamically significant 53 metastatic GIST 53 CMV seropositive 53 low dose Iluvien 53 STRIDE PD 53 achieved sustained virological 53 laboratory abnormalities 53 reperfusion 53 acute coronary syndromes 53 lumen diameter 53 CDAI 53 HAM D# scores 53 thinner struts 53 HES CEL 53 HbA1c levels 53 ug dose 53 probable stent thrombosis 53 trabeculectomy 53 VcMP 53 ACEI ARB 53 periprocedural MI 53 hemodialysis patients 53 macrovascular events 53 Endeavor stent 53 DAS# [002] 53 beta blocker therapy 53 carotid endarterectomy CEA 53 mcg QD 53 HbA1C levels 53 coronary revascularizations 53 CIMZIA TM certolizumab pegol 53 thrombolysis 53 pegylated liposomal doxorubicin 53 glimepiride 53 Folfox 53 #mg BID [001] 53 cardiogenic shock 53 atherothrombosis 53 residual stenosis 53 Patency 53 liver transplant recipients 53 clodronate 53 virologic response 53 REYATAZ r arm 53 SVR# 53 Castration Resistant Prostate Cancer 53 placebo fluoxetine 53 comparator arm 52 nonischemic 52 Val HeFT 52 transplantation HCT 52 sidebranch 52 LVSD 52 A1C levels 52 evaluable subjects 52 Expanded Disability Status 52 RGT arm 52 malignant neoplasm 52 myocardial infarction ventricular fibrillation 52 leukocyte count 52 NATRECOR ® 52 EBRT 52 CNS systemic embolism 52 % CI #.#-#.# [005] 52 EDSS scores 52 pyrexia mucositis sepsis febrile 52 ventricular tachycardia VT 52 SUVmax 52 response CCyR 52 Atom Stent 52 descending thoracic 52 p = #.# [002] 52 bypass grafts 52 endophthalmitis 52 TAXUS V 52 prospectively defined 52 carboplatin chemotherapy 52 urgent revascularization 52 % CI #.#-#.# [007] 52 confirmed CCyR 52 unresectable 52 oral antidiabetic medication 52 Hazard Ratio 52 confidence interval #.#-#.# 52 coronary revascularization procedures 52 transthoracic 52 paroxysmal atrial fibrillation 52 infarctions 52 thrombolytic therapy 52 subtrochanteric 52 aspirin heparin 52 functional mitral regurgitation 52 standard chemotherapy regimen 52 segment elevation myocardial 52 relapsed refractory multiple myeloma 52 pT3 52 TRITON TIMI 52 FOLFOX4 alone 52 adrenalectomy 52 noncardiac 52 FIRMAGON 52 clinically evaluable patients 52 p = #.# [003] 52 CIMZIA TM 52 imipenem 52 myocardial ischemia 52 NPH insulin 52 antegrade 52 oxycodone IR 52 sUA 52 REMICADE monotherapy 52 #mg QD [002] 52 arteriovenous fistula 52 recurrent stroke 52 microvascular disease 52 resynchronization therapy 52 CI #.#-#.# [002] 52 graft dysfunction 52 bivalirudin alone 52 complete cytogenetic response 52 cardiopulmonary bypass CPB 52 stroke myocardial infarction 52 undergoing coronary angiography 52 enoxaparin 52 bowel resection 52 intraoperative complications 52 liver resection 52 thrombocytopenic 52 mediastinitis 52 serum phosphorous 52 salpingo oophorectomy 52 undergo percutaneous coronary 52 limb salvage 52 concurrent chemoradiation 52 artery reclogging 52 catheter angiography 52 albumin excretion rate 52 infarction 52 liver metastases 52 patients evaluable 52 median sternotomy 52 mcg kg REBETOL 52 complete remissions 52 TEVAR 52 MADIT II 52 experienced virologic failure 52 debulking surgery 52 methotrexate monotherapy 52 NYHA class 52 ximelagatran 52 heavily pretreated 52 ATACAND 52 pancreatic resection 52 Peripheral vascular 52 lung metastases 52 pneumonectomy 52 pericardial effusion 52 valvular disease 52 crossclamp 52 endothelial keratoplasty 52 CRp 52 radiochemotherapy 52 radial artery grafts 52 tipranavir r 52 systolic hypertension 52 Genous stent 52 drug eluting stent 52 cerebral vasospasm 52 CVD mortality 52 Express2 TM paclitaxel eluting 52 EDSS score 52 MCyR 52 homograft 52 mg BID 52 mL/min/#.# m 2 52 recurrent ischemic 52 intravesical therapy 52 pump IABP 52 nodal metastases 52 APTIVUS r 52 recurrent coronary 52 angiographic follow 52 nephron sparing surgery 52 adjunctive ABILIFY 52 endovascular repair 52 aldosterone antagonist 52 specific antigen PSA 52 mg kg belimumab 52 drug zotarolimus 52 neoadjuvant chemotherapy 52 hemodynamic instability 52 partial remissions 52 SORT OUT III 52 endovascular therapy 52 TAXUS stents 52 paclitaxel eluting 52 Intracranial 52 INTERMACS 52 sinus rhythm 52 cardiac resynchronization 52 undergoing percutaneous coronary 52 cystectomy 52 acute STEMI 52 Ejection Fraction 52 saphenous vein graft 52 chemoembolization 52 unstable angina 51 PREZISTA r arm 51 dacarbazine 51 bypass graft 51 ribavirin therapy 51 pulsatile flow 51 vertebral fractures 51 Baseline characteristics 51 XELOX 51 Acute Myocardial Infarction 51 Myocardial Infarction MI 51 Sustained virologic response 51 carboplatin paclitaxel 51 insulin detemir 51 symptomatic atrial fibrillation 51 metoprolol tartrate 51 intracerebral hemorrhage 51 noninferiority 51 drotrecogin alfa activated 51 mitral regurgitation 51 ARB telmisartan 51 atherothrombotic events 51 SYNERGY Stent 51 clinically localized prostate 51 febrile neutropenia 51 valsartan 51 mg qd 51 Percutaneous Transluminal Coronary Angioplasty 51 highest tertile 51 hemoglobin A1c HbA1c 51 intracerebral hemorrhages 51 recurrent atrial fibrillation 51 TAXUS R 51 5-FU/LV 51 drug eluting stent implantation 51 vein grafts 51 nocturnal hypoglycaemia 51 endothelialization 51 Ischemic stroke 51 evaluable patients 51 anginal symptoms 51 lipid lowering agents 51 #mg BID [003] 51 coronary artery stenosis 51 anticoagulation therapy 51 mcg BID 51 acute decompensation 51 upper gastrointestinal bleeding 51 palliation 51 renal artery stenosis 51 mg Lucentis 51 tumor progression TTP 51 TAXUS Liberte 51 carotid surgery 51 LAGB 51 Amrubicin 51 TURP 51 epirubicin cyclophosphamide 51 paclitaxel stent 51 NEVO TM 51 CMV disease 51 IIIa inhibitors 51 artery bypass 51 HbA 1c 51 dose pravastatin 51 antithrombotic therapy 51 naïve HCV 51 ST Segment Elevation 51 GP IIb IIIa inhibitors 51 onset diabetes mellitus 51 thrombolytic agents 51 -#.# log# copies mL 51 LOVENOX 51 TAXUS Express2 paclitaxel eluting 51 bivalirudin monotherapy 51 log# IU mL 51 Coronary artery bypass graft 51 dose statin therapy 51 #.#mg/dL 51 degarelix 51 CABG coronary artery 51 hsCRP levels 51 SGRQ 51 revascularisation procedures 51 transplant ASCT 51 surgical revascularization 51 intra aortic balloon 51 % Confidence Interval 51 nadroparin 51 antiplatelet therapy 51 epicardial 51 retransplantation 51 TNF antagonist 51 thoracic aortic 51 nonresponders 51 CK # plasma concentrations 51 hematologic toxicity 51 pulmonary embolism PE 51 neutrophil counts 51 % CI #.#-#.# [006] 51 cholecystectomy 51 metastatic CRC 51 IBDQ 51 GP IIb IIIa inhibitor 51 mcg Albuferon 51 mg BID dose 51 bi ventricular pacing 51 mmHg 51 BEACOPP 51 noninferior 51 chemoradiation 51 DAS# scores 51 generalized edema 51 TM Drug Eluting 51 paclitaxel cisplatin 51 Rating Scale MADRS 51 antiarrhythmic drug 51 intravascular hemolysis 51 mcg kg 51 postoperative complications 51 DES implantation 51 Endeavor drug eluting 51 statistically significant p = 51 colorectal adenoma 51 candesartan 51 kidney transplant recipients 51 plus MTX 51 sternal wound infection 51 locoregional 51 clopidogrel 51 recurrent DVT 51 gemcitabine Gemzar 51 thromboses 51 TURBT 51 STEMI ST 51 recurrent glioblastoma multiforme 51 ascending aortic 51 venous thromboembolism 51 tumor shrinkage 51 hematologic adverse 51 FluCAM arm 51 cyclophosphamide methotrexate 51 chemoradiation therapy 51 bilateral TKA 51 receiving golimumab 51 clinicopathological features 51 carotid intima media 51 dose dexamethasone 51 cerebrovascular accident 51 MULTI LINK VISION 51 PICSO ® 51 metastatic renal cell carcinoma 51 replacement PAVR 51 relapsed MM 51 radial artery 51 chemoradiotherapy 51 cisplatin gemcitabine 51 doxorubicin docetaxel 51 4mg/kg 51 Coronary Artery Bypass Grafting 51 perioperatively 51 ejection fraction 51 cytoreduction 51 postprocedure 51 total knee arthroplasty 51 sleeve lobectomy 51 cardiopulmonary bypass 51 tortuosity 51 ARCALYST ® 51 reperfusion therapy 51 elevated IOP 51 Median PFS 51 nonoperative treatment 51 NSTEMI 51 Ishak fibrosis score 51 adalimumab 51 leiomyomas 51 radical cystectomy 51 angiotensin converting enzyme inhibitor 51 ischemic 51 β blockers 51 gout flares 51 Elitek 51 serum urate 51 systolic function 51 p = 51 telaprevir dosed 51 prednisone prednisolone plus 51 virological failure 51 ejection fraction EF 51 ng dL 50 acute myocardial infarctions 50 relapsed SCLC 50 serum aminotransferase levels 50 recurrent NSCLC 50 perioperative morbidity 50 events AEs 50 IV NSCLC 50 serum potassium 50 fractional shortening 50 Tumor shrinkage 50 cardiac toxicity 50 ropivacaine 50 advanced adenoma 50 antiplatelet agent 50 Thal Dex 50 PCIs 50 CR CRu 50 radical retropubic prostatectomy 50 elevated triglyceride levels 50 glycosylated hemoglobin HbA1c 50 antithrombotic therapies 50 peginterferon alfa 2a 50 Coronary artery bypass grafting 50 preserved ejection fraction 50 chemotherapy gemcitabine 50 -#.# mg dL [001] 50 aortic stenosis 50 angioplasties stents 50 ticagrelor 50 intravitreal injections 50 lymphopenia 50 nodular partial response 50 nab paclitaxel 50 left ventricular ejection 50 carotid artery stenting 50 glycoprotein IIb IIIa inhibitors 50 Oral Cavity Soft Palate 50 mCi kg 50 colorectal metastases 50 -#.# log# 50 oral Hycamtin 50 saline placebo 50 aneurysm ruptures 50 PRADAXA #mg 50 #mg BID [002] 50 severe hypoglycemia 50 doxorubicin cyclophosphamide 50 Edwards SAPIEN XT 50 dose cytarabine 50 EGFR expressing mCRC 50 pancreatectomy 50 Embolic Protection Device 50 infective endocarditis 50 aneurysm rupture 50 cerebral ischemia 50 QTcF 50 preserved systolic 50 #mg/m# [001] 50 distal embolization thrombus formation 50 Score IPSS 50 antiplatelet drugs 50 decompensated heart failure 50 Radical prostatectomy 50 CsA 50 foveal thickness 50 Unified Parkinson Disease 50 iniparib BSI 50 mutated KRAS 50 chronic GVHD 50 achieving PASI 50 oral diclofenac 50 REYATAZ r 50 nonvertebral 50 mRCC 50 transcatheter closure 50 fluvastatin 50 angina pectoris 50 simvastatin ezetimibe 50 glomerular filtration 50 Anti Bacterial Envelope 50 baseline serum creatinine 50 timepoints 50 Solid Tumors criteria 50 intimal hyperplasia 50 plasma uric acid 50 femoral popliteal 50 SLNB 50 eGFR 50 uncoated stents 50 dalteparin 50 VIRAMUNE 50 recurrent venous thromboembolism 50 CRESTOR #mg 50 gadolinium enhancing lesions 50 x ULN 50 Cystectomy 50 azacitidine 50 ribavirin RBV 50 occluded artery 50 #.#mmol L [001] 50 glycoprotein IIb IIIa inhibitor 50 mg/m2 dose 50 idraparinux 50 thoracotomy 50 Left Ventricular Ejection Fraction 50 drug eluting coronary stents 50 TMC# r 50 interferon alfa 2a 50 5-fluorouracil/leucovorin 50 stable angina pectoris 50 lung esophageal 50 abacavir lamivudine 50 seroprotection 50 plus glycoprotein IIb 50 coronary artery bypass 50 cerebral angiography 50 bortezomib refractory 50 lobectomy 50 ADAS cog 50 ExTRACT TIMI 50 hepatic metastases 50 liver metastasis 50 rimonabant #mg 50 sunitinib Sutent 50 Cardiopulmonary bypass 50 pegylated interferon alfa 2b 50 plus aztreonam 50 #.#ng/ml 50 cardiovascular mortality 50 ostial 50 drug eluting stent DES 50 preoperative PSA